A Preview Of BioLine Rx's Earnings
Portfolio Pulse from Benzinga Insights
BioLine Rx (NASDAQ:BLRX) is set to release its latest quarterly earnings report on August 30, 2023. Analysts estimate an earnings per share (EPS) of $-0.11. The company's past performance shows a mixed trend of beating and missing EPS estimates, which has resulted in varied stock price changes. The stock is currently trading at $1.28, down 13.0% over the last 52-week period.
August 29, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BioLine Rx is expected to report an EPS of $-0.11 in its upcoming earnings. The stock has seen a 13.0% decline over the past year. The company's earnings announcement could potentially influence its stock price.
BioLine Rx's earnings report is a significant event that could influence its stock price. The company's past performance shows a mixed trend of beating and missing EPS estimates, which has resulted in varied stock price changes. Given the stock's 13.0% decline over the past year, the upcoming earnings announcement could potentially sway investor sentiment and impact the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100